Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 1/2017

01-03-2017 | Original Research

Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus

Authors: Abhinav Dewan, SK Sharma, AK Dewan, Ruparna Khurana, Manoj Gupta, Anjali Pahuja, Himanshu Srivastava, Rupal Sinha

Published in: Journal of Gastrointestinal Cancer | Issue 1/2017

Login to get access

Abstract

Background

Neoadjuvant chemoradiation (NCRT) has been shown to improve survival in patients with locally advanced esophageal squamous cell carcinoma (SCC). The aim of the present study was to evaluate the role of 18-FDG PET-CT in predicting pathological response to NCRT.

Material and Methods

We assessed 70 patients of esophageal SCC who underwent NCRT and were evaluated with baseline and post chemoradiation 18F-FDG PET-CT scan. Receiver operating characteristic (ROC) curve was generated by analyzing the sensitivity and specificity of different cut-off points for defining a positive test and their ability to predict pathological complete response. Univariate and multivariate analysis were performed using log-rank and Cox proportional hazards models, and survival curves were estimated using the Kaplan-Meier method.

Results

Radiological and pathological complete response was achieved in 44.3 % (n = 31) and 34.3 % (n = 24) patients, respectively. Using ROC curves, post-treatment standardized uptake value (SUV) max [3.25, area under curve (AUC) 0.752] and % change in SUVmax cut-off value (72.32 %, AUC 0.705) was used to predict pathological response. Significant associations between pathological response in primary tumor and post chemotherapy/radiotherapy SUVmax values (p = 0.016), % change in SUVmax (p = 0.006), radiological response in primary (p = 0.006), and grade of dysphagia at presentation (p = 0.041) were observed. Mean overall survival and relapse free survival was 83 and 58 %, respectively at 34 months.

Conclusion

18F-FDG PET-CT can be used to predict pathological response to NCRT in locally advanced SCC.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA. Cancer J Clin. 2011; Mar-Apr61(2):69–90.CrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA. Cancer J Clin. 2011; Mar-Apr61(2):69–90.CrossRef
3.
go back to reference Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.CrossRefPubMed Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.CrossRefPubMed
4.
go back to reference Donington JS, Miller DL, Allen MS, et al. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg. 2003;24:631–7.CrossRefPubMed Donington JS, Miller DL, Allen MS, et al. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg. 2003;24:631–7.CrossRefPubMed
5.
go back to reference Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–10.PubMed Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–10.PubMed
6.
go back to reference Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 1997;64:770–7.CrossRefPubMed Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 1997;64:770–7.CrossRefPubMed
7.
go back to reference Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys. 1995;31(5):1213–36.CrossRefPubMed Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys. 1995;31(5):1213–36.CrossRefPubMed
8.
go back to reference Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving. Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.CrossRefPubMedPubMedCentral Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving. Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.CrossRefPubMedPubMedCentral
9.
go back to reference Urschel JD, Vasan HA. Meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185(6):538–43.CrossRefPubMed Urschel JD, Vasan HA. Meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185(6):538–43.CrossRefPubMed
10.
go back to reference Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53(7):925–30.CrossRefPubMedPubMedCentral Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53(7):925–30.CrossRefPubMedPubMedCentral
11.
go back to reference Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.CrossRefPubMed Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.CrossRefPubMed
13.
go back to reference Brucher B, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300–9.CrossRefPubMedPubMedCentral Brucher B, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300–9.CrossRefPubMedPubMedCentral
14.
go back to reference Kato H, Kuwano H, Nakajima M. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg. 2002;184:279–83.CrossRefPubMed Kato H, Kuwano H, Nakajima M. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg. 2002;184:279–83.CrossRefPubMed
15.
go back to reference Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Onc. 2002;13:361–8.CrossRef Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Onc. 2002;13:361–8.CrossRef
16.
go back to reference Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428–32.CrossRefPubMed Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428–32.CrossRefPubMed
17.
go back to reference Luketich JD, Schauer PR, Meltzer CC, et al. Role of positronemission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64:765–9.CrossRefPubMed Luketich JD, Schauer PR, Meltzer CC, et al. Role of positronemission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64:765–9.CrossRefPubMed
18.
go back to reference Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999;68:1133–7.CrossRefPubMed Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999;68:1133–7.CrossRefPubMed
19.
go back to reference Kim K, Park SJ, Kim B-T, et al. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001;71:290–4.CrossRefPubMed Kim K, Park SJ, Kim B-T, et al. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001;71:290–4.CrossRefPubMed
20.
go back to reference Yoon YC, Lee KS, Shim YM, et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection—prospective study. Radiology. 2003;227:764–70.CrossRefPubMed Yoon YC, Lee KS, Shim YM, et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection—prospective study. Radiology. 2003;227:764–70.CrossRefPubMed
21.
go back to reference Mandard A, Dalibard F, Mandard JC, et al. Pathologic assessment of tumour regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73:2680–6.CrossRefPubMed Mandard A, Dalibard F, Mandard JC, et al. Pathologic assessment of tumour regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73:2680–6.CrossRefPubMed
22.
go back to reference Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int JRadiat Oncol Biol Phys. 2005;63(4):1053.CrossRef Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int JRadiat Oncol Biol Phys. 2005;63(4):1053.CrossRef
23.
go back to reference DeYoung CM, Suntharalingam M, Line BR, et al. The ability of whole-body FDG 18 PET imaging to predict pathologic response to induction chemoradiotherapy in locally advanced esophageal cancer: a prospective phase II trial [abstract. Int J Radiat Oncol Biol Phys. 2003;57(Suppl. 2):S165–6.CrossRef DeYoung CM, Suntharalingam M, Line BR, et al. The ability of whole-body FDG 18 PET imaging to predict pathologic response to induction chemoradiotherapy in locally advanced esophageal cancer: a prospective phase II trial [abstract. Int J Radiat Oncol Biol Phys. 2003;57(Suppl. 2):S165–6.CrossRef
24.
go back to reference Makino T, Doki Y, Miyata H, et al. Use of (18) F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvantchemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery. 2008;144:793–802.CrossRefPubMed Makino T, Doki Y, Miyata H, et al. Use of (18) F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvantchemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery. 2008;144:793–802.CrossRefPubMed
25.
go back to reference Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472–8.CrossRefPubMedPubMedCentral Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472–8.CrossRefPubMedPubMedCentral
26.
go back to reference Poplin E, Fleming T, Leichman L, et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG −8037. J Clin Oncol. 1987;5:622–8.PubMed Poplin E, Fleming T, Leichman L, et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG −8037. J Clin Oncol. 1987;5:622–8.PubMed
27.
go back to reference Seydel HG, Leichman L, Byhardt R, et al. Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG study. Int J Radiat Oncol Biol Phys. 1988;14:33–5.CrossRefPubMed Seydel HG, Leichman L, Byhardt R, et al. Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG study. Int J Radiat Oncol Biol Phys. 1988;14:33–5.CrossRefPubMed
28.
go back to reference Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118–23.PubMed Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118–23.PubMed
29.
go back to reference Wolfe WG, Vaughn AL, Seigler HF, et al. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg. 1993;105:749–56.PubMed Wolfe WG, Vaughn AL, Seigler HF, et al. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg. 1993;105:749–56.PubMed
30.
go back to reference Forastiere AA, Heitmiller RF, Lee DJ, et al. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am. 1997;3:144–52.PubMed Forastiere AA, Heitmiller RF, Lee DJ, et al. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am. 1997;3:144–52.PubMed
31.
go back to reference Van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMed Van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMed
32.
go back to reference Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.CrossRefPubMed Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.CrossRefPubMed
33.
go back to reference Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;9:659–68.CrossRef Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;9:659–68.CrossRef
34.
go back to reference Vallböhmer D, Hölscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252:744–9.CrossRefPubMed Vallböhmer D, Hölscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252:744–9.CrossRefPubMed
35.
go back to reference Law S, Kwong DL, Kwok KF, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238(3):339–47.PubMedPubMedCentral Law S, Kwong DL, Kwok KF, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238(3):339–47.PubMedPubMedCentral
36.
go back to reference Rawat S, Kumar G, Kakria A, et al. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required? J Gastrointestinal Cancer. 2013;44(3):277–84. doi:10.1007/s12029-013-9477-7.CrossRefPubMed Rawat S, Kumar G, Kakria A, et al. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required? J Gastrointestinal Cancer. 2013;44(3):277–84. doi:10.​1007/​s12029-013-9477-7.CrossRefPubMed
37.
go back to reference Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507–12.CrossRefPubMed Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507–12.CrossRefPubMed
38.
go back to reference Rizk NP, Seshan VE, Bains MS, et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007;2:1117–23.CrossRefPubMed Rizk NP, Seshan VE, Bains MS, et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007;2:1117–23.CrossRefPubMed
39.
go back to reference Chen WH, Huang YL, Chao YK, et al. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2015;22(1):338–43. doi:10.1245/s10434-014-3881-5.CrossRefPubMed Chen WH, Huang YL, Chao YK, et al. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2015;22(1):338–43. doi:10.​1245/​s10434-014-3881-5.CrossRefPubMed
Metadata
Title
Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus
Authors
Abhinav Dewan
SK Sharma
AK Dewan
Ruparna Khurana
Manoj Gupta
Anjali Pahuja
Himanshu Srivastava
Rupal Sinha
Publication date
01-03-2017
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 1/2017
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9870-0

Other articles of this Issue 1/2017

Journal of Gastrointestinal Cancer 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.